Optimizing Size and Copy Number For PEG-fMLF (N-Formyl-methionyl-leucyl-phenylalanine) Nanocarrier Uptake by Macrophages
- 20 December 2007
- journal article
- research article
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 19 (1), 28-38
- https://doi.org/10.1021/bc070066k
Abstract
Curing HIV-1 infection has remained elusive because of low and fluctuating drug levels arising from poor absorption, the development of viral reservoirs and sanctuary sites, toxicity, and patient nonadherence. The present study addresses the issue of insufficient drug exposure in macrophages. Viral reservoir sites such as macrophages are believed to be responsible for the viral rebound effect observed upon the discontinuation of anti-HIV drug therapy. In our proposed model, a drug can be covalently attached to a nanocarrier in order to facilitate the delivery of therapeutic agents to the site(s) of infection. As an initial step, we propose the covalent attachment of several copies of N-formyl-Met-Leu-Phe (fMLF), a known chemo-attractant for macrophages. In this article, one or more copies of fMLF were conjugated to multifunctional commercially available or novel, peptide-based PEG nanocarriers in which the structure was varied by appending PEGs with average molecular weights of 5, 20, and 40 kDa. U937 cell-specific binding and cellular uptake were analyzed. The results of uptake studies indicate that (i) uptake is energy dependent and mediated by a fMLF receptor, (ii) appending only 2 copies of the targeting ligand to the multifunctional nanocarrier appears sufficient for binding in vitro, and (iii) of the three configurations studied, the nanocarrier with a molecular weight of about 20 kDa, corresponding to a size of 20–60 nm, demonstrated the highest uptake. The results of the current studies demonstrate the feasibility of targeting macrophages and the suitability of using these synthetically versatile peptide−backbone PEG nanocarriers. The convenience, flexibility and possible limitations of this nanocarrier approach are discussed.Keywords
This publication has 32 references indexed in Scilit:
- Tuftsin-AZT conjugate: potential macrophage targeting for AIDS therapyJournal of Peptide Science, 2004
- Pharmacokinetic and biodistribution properties of poly(ethylene glycol)–protein conjugatesAdvanced Drug Delivery Reviews, 2003
- Remarkably Size-Regulated Cell Invasion by Artificial Viruses. Saccharide-Dependent Self-Aggregation of Glycoviruses and Its Consequences in Glycoviral Gene DeliveryJournal of the American Chemical Society, 2003
- PEG drugs: an overviewJournal of Controlled Release, 2001
- HIV chemotherapyNature, 2001
- PegylationClinical Pharmacokinetics, 2001
- The N-formyl peptide receptor: A model for the study of chemoattractant receptor structure and functionPharmacology & Therapeutics, 1997
- Homozygous Defect in HIV-1 Coreceptor Accounts for Resistance of Some Multiply-Exposed Individuals to HIV-1 InfectionCell, 1996
- Development of specific receptors for N-formylated chemotactic peptides in a human monocyte cell line stimulated with lymphokinesThe Journal of Experimental Medicine, 1980
- Receptor-Mediated Internalization of Fluorescent Chemotactic Peptide by Human NeutrophilsScience, 1979